CAS NO: | 2068-78-2 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
1 g | 电议 |
生物活性 | Vincristine sulfate is an antitumor vinca alkaloid which inhibitsmicrotubuleformation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. It binds tomicrotubulewith aKiof 85 nM. | ||||||||||||||||
体外研究 (In Vitro) | Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM[1]. Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis at low concentrations. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules[2]. Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D[3]. Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration[4]. | ||||||||||||||||
体内研究 (In Vivo) | Vincristine (3 mg/kg, i.p.) induces mean growth delay of >120 and >52 day, and repopulates fractions of 0.06% and 5%, administrated in mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, respectively[5]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 923.04 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C46H58N4O14S | ||||||||||||||||
CAS 号 | 2068-78-2 | ||||||||||||||||
中文名称 | 硫酸长春新碱;硫酸长春醛碱;长春新碱硫化物;长春新碱硫酸盐 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
来源 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 83.33 mg/mL(90.28 mM;ultrasonic and warming and heat to 80℃) H2O : 50 mg/mL(54.17 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|